دورية أكاديمية
Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and disease severity in patients at high risk for hereditary thrombophilia.
| العنوان: | Contribution of genotypes in Prothrombin and Factor V Leiden to COVID-19 and disease severity in patients at high risk for hereditary thrombophilia. |
|---|---|
| المؤلفون: | Kiraz A; Kayseri City Training and Research Hospital, Genetic Diseases Evaluation Center, Kayseri, Turkey., Sezer O; Samsun Training and Research Hospital, Genetic Diseases Evaluation Center, Samsun, Turkey., Alemdar A; Department of Translational Medicine, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey., Canbek S; Umraniye Training and Research Hospital, Genetic Diseases Evaluation Center, Health Sciences University, Istanbul, Turkey., Duman N; Department of Medical Genetics, Dragos Hospital, Bezmialem Vakıf University, Istanbul, Turkey., Bisgin A; Medical Genetics Department of Medical Faculty, AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Cukurova University, Adana, Turkey., Cora T; Department of Medical Genetics, Faculty of Medicine, Selcuk University, Konya, Turkey., Ruhi HI; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Ergoren MC; Department of Medical Genetics, Faculty of Medicine, Near East University, Nicosia, Cyprus., Geçkinli BB; Department of Medical Genetics, Faculty of Medicine, Marmara University, Istanbul, Turkey., Sag SO; Department of Medical Genetics, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey., Gözden HE; Department of Translational Medicine, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.; Department of Haematology, Bursa Yuksek Ihtısas Training and Research Hospital, Health Sciences University, Bursa, Turkey., Oz O; Department of Medical Genetics, Faculty of Medicine, Harran University, Sanlıurfa, Turkey., Altıntaş ZM; Department of Medical Genetics, Faculty of Medicine, Mersin University, Mersin, Turkey., Yalcıntepe S; Department of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey., Keskin A; Department of Biochemistry, Institute of Health Sciences, Adnan Menderes University, Aydın, Turkey., Tak AY; Department of Biostatistics and Medical Informatics, Faculty of Medicine, Bezmialem Vakıf University, Istanbul, Turkey., Paskal ŞA; Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkey., Yürekli UF; Department of Medical Biochemistry, Sanlıurfa Mehmet Akif İnan Health Application and Research Center, Health Sciences University, Sanlıurfa, Turkey., Demirtas M; Mikrogen Genetic Diagnosis Laboratory, Ankara, Turkey., Evren EU; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Kyrenia, Kyrenia, Cyprus., Hanta A; Cukurova University AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Adana, Turkey., Başdemirci M; Konya Training and Research Hospital, Genetic Diseases Evaluation Center, Health Sciences University, Konya, Turkey., Suer K; Department of Infectious Diseases and Clinicai Microbiology, Faculty of Medicine, Near East University, Nicosia, Cyprus., Balta B; Kayseri City Training and Research Hospital, Genetic Diseases Evaluation Center, Kayseri, Turkey., Kocak N; Department of Medical Genetics, Faculty of Medicine, Selcuk University, Konya, Turkey., Karabulut HG; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Cobanogulları H; DESAM Institute, Near East University, Nicosia, Cyprus., Ateş EA; Department of Medical Genetics, Faculty of Medicine, Marmara University, Istanbul, Turkey., Bozdoğan ST; Medical Genetics Department of Medical Faculty, AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Cukurova University, Adana, Turkey., Eker D; Department of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey., Ekinci S; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Nergiz S; Department of Medical Genetics, Faculty of Medicine, Selcuk University, Konya, Turkey., Tuncalı T; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Yagbasan S; Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkey., Alavanda C; Department of Medical Genetics, Faculty of Medicine, Marmara University, Istanbul, Turkey., Kutlay NY; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Evren H; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Kyrenia, Kyrenia, Cyprus., Erdoğan M; Kayseri City Training and Research Hospital, Genetic Diseases Evaluation Center, Kayseri, Turkey., Altıner S; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Sanlidag T; DESAM Institute, Near East University, Nicosia, Cyprus., Gonen GA; Kayseri City Training and Research Hospital, Genetic Diseases Evaluation Center, Kayseri, Turkey., Vicdan A; Department of Medical Genetics, Faculty of Medicine, Ankara University, Ankara, Turkey., Eras N; Department of Medical Genetics, Faculty of Medicine, Mersin University, Mersin, Turkey., Eker HK; Konya Training and Research Hospital, Genetic Diseases Evaluation Center, Health Sciences University, Konya, Turkey., Balasar O; Konya Training and Research Hospital, Genetic Diseases Evaluation Center, Health Sciences University, Konya, Turkey., Tuncel G; DESAM Institute, Near East University, Nicosia, Cyprus., Dundar M; Department of Medical Genetics, Faculty of Medicine, Erciyes University, Kayseri, Turkey., Gurkan H; Department of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey., Temel SG; Department of Translational Medicine, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey.; Department of Medical Genetics, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.; Department of Medical Genetics, Health Sciences Institute, Baskent University, Ankara, Turkey. |
| المصدر: | Journal of medical virology [J Med Virol] 2023 Feb; Vol. 95 (2), pp. e28457. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | COVID-19* , Thrombophilia*/epidemiology , Thrombophilia*/genetics , Thrombosis*, Humans ; Male ; Female ; Prothrombin/genetics ; Risk Factors ; SARS-CoV-2 ; Genotype ; Factor V/genetics ; Patient Acuity ; Mutation |
| مستخلص: | Thrombotic and microangiopathic effects have been reported in COVID-19 patients. This study examined the contribution of the hereditary thrombophilia factors Prothrombin (FII) and Factor V Leiden (FVL) genotypes to the severity of COVID-19 disease and the development of thrombosis. This study investigated FII and FVL alleles in a cohort of 9508 patients (2606 male and 6902 female) with thrombophilia. It was observed that 930 of these patients had been infected by SARS-CoV-2 causing COVID-19. The demographic characteristics of the patients and their COVID-19 medical history were recorded. Detailed clinical manifestations were analyzed in a group of cases (n = 4092). This subgroup was age and gender-matched. FII and FVL frequency data of healthy populations without thrombophilia risk were obtained from Bursa Uludag University Medical Genetic Department's Exome Databank. The ratio of males (31.08%; 27.01%) and the mean age (36.85 ± 15.20; 33.89 ± 14.14) were higher among COVID-19 patients compared to non-COVID-19 patients. The prevalence of FVL and computerized tomography (CT) positivity in COVID-19 patients was statistically significant in the thrombotic subgroup (p < 0.05). FVL prevalence, CT positivity rate, history of thrombosis, and pulmonary thromboembolism complication were found to be higher in deceased COVID-19 patients (p < 0.05). Disease severity was mainly affected by FVL and not related to genotypes at the Prothrombin mutations. Overall, disease severity and development of thrombosis in COVID-19 are mainly affected by the variation within the FVL gene. Possible FVL mutation should be investigated in COVID-19 patients and appropriate treatment should be started earlier in FVL-positive patients. (© 2023 Wiley Periodicals LLC.) |
| References: | Jarjour RA, Ammar S, Majdalawi R. Frequency of three prothrombotic polymorphisms among Syrian population: factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T. Ann Hum Biol. 2017;44(1):70-73. doi:10.3109/03014460.2015.1119308. Badulescu OV, Sirbu PD, Filip N, et al. Hereditary thrombophilia in the era of COVID-19. Healthcare (Basel). 2022;10(6):993. doi:10.3390/healthcare10060993. Dautaj A, Krasi G, Bushati V, et al. Hereditary thrombophilia. Acta Biomed. 2019;90(10-S):44-46. doi:10.23750/abm.v90i10-S.8758. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009-1016. doi:10.1136/thoraxjnl-2020-215314. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med. 2020;8(7):497. doi:10.21037/atm.2020.03.157. Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi:10.1136/bmj.n436. Mansory EM, Srigunapalan S, Lazo-Langner A. Venous thromboembolism in hospitalized critical and noncritical COVID-19 patients: a systematic review and meta-analysis. TH Open. 2021;5(3):e286-e294. doi:10.1055/s-0041-1730967. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424. doi:10.1111/jth.14830. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. doi:10.1016/S2213-2600(20)30243-5. Zguro K, Baldassarri M, Fava F, et al. Carriers of ADAMTS13 rare variants are at high risk of life-threatening COVID-19. Viruses. 2022;14(6):1185. doi:10.3390/v14061185. Zdanyte M, Rath D, Gawaz M, Geisler T. Venous thrombosis and SARS-CoV-2. Hamostaseologie. 2022;42(4):240-247. doi:10.1055/a-1661-0283. Voigtlaender M, Edler C, Gerling M, et al. Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: frequency, characteristics and risk factors. Thromb Res. 2022;218:171-176. doi:10.1016/j.thromres.2022.08.021. Xie J, Prats-Uribe A, Feng Q, et al. Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. JAMA Intern Med. 2022;182(10):1063-1070. doi:10.1001/jamainternmed.2022.3858. Erratum in: JAMA Intern Med. 2022;182(11):1234. Elbadry MI, Tawfeek A, Abdellatif MG, et al. Unusual pattern of thrombotic events in young adult non-critically ill patients with COVID-19 may result from an undiagnosed inherited and acquired form of thrombophilia. Br J Haematol. 2022;196(4):902-922. doi:10.1111/bjh.17986. Erratum in: Br J Haematol. 2022;198(1):214. Kiraz A, Guzeldag S, Eren E, Goksu M, Bayram A. Investigation of the relationship between inherited thrombophilia and novel coronavirus pneumonia. Future Virol. 2021;16(5):341-345. doi:10.2217/fvl-2020-0395. Sezer O, Gunal O, Aci R, Keskin A. Possible effect of genetic background in thrombophilia genes on clinical severity of patients with coronavirus disease-2019: a prospective cohort study. Baghdad J Biochem Appl Biol Sci. 2022;3(03):183-199. doi:10.47419/bjbabs.v3i03.141. Kabukcu S, Keskin N, Keskin A, Atalay E. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey. Clin Appl Thromb Hemost. 2007;13(2):166-171. doi:10.1177/1076029606298990. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134. Raptopoulou A, Michou V, Mourtzi N, et al. Large-scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population. Health Sci Rep. 2022;5(4):e457. doi:10.1002/hsr2.457. Eroglu A, Sertkaya D, Akar N. The role of Factor V Leiden in adult patients with venous thromboembolism: a meta-analysis of published studies from Turkey. Clin Appl Thromb Hemost. 2012;18:40-44. Senturk A. Hereditary thrombophilia. Güncel Göğüs Hastalıkları Serisi. 2015;3(1):16-23. Wawrusiewicz-Kurylonek N, Krętowski AJ, Posmyk R. Frequency of thrombophilia associated genes variants: population-based study. BMC Med Genet. 2020;21(1):198. doi:10.1186/s12881-020-01136-5. Liu R, Han H, Liu F, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta. 2020;505:172-175. doi:10.1016/j.cca.2020.03.009. Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149. doi:10.1177/1076029620938149. Zhang N, Xu X, Zhou LY, et al. Clinical characteristics and chest CT imaging features of critically ill COVID-19 patients. Eur Radiol. 2020;30(11):6151-6160. doi:10.1007/s00330-020-06955-x. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135-1140. doi:10.1016/S1473-3099(20)30434-5. Corey KM, Olson LB, Naqvi IA, et al. Suppression of fibrinolysis and hypercoagulability, severity of hypoxemia, and mortality in COVID-19 patients: a retrospective cohort study. Anesthesiology. 2022;137(1):67-78. doi:10.1097/ALN.0000000000004239. Lapić I, Radić Antolic M, Horvat I, et al. Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: a pilot study. J Med Virol. 2022;94(8):3669-3675. doi:10.1002/jmv.27774. Poredoš P. Interrelationship between venous and arterial thrombosis. Int Angiol. 2017;36(4):295-298. doi:10.23736/S0392-9590.17.03820-2. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639. doi:10.1016/j.eclinm.2020.100639. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786-787. doi:10.1111/jth.14781. |
| فهرسة مساهمة: | Keywords: COVID-19; Factor V Leiden; Prothrombin; thrombophilia |
| المشرفين على المادة: | 9001-26-7 (Prothrombin) 0 (factor V Leiden) 9001-24-5 (Factor V) |
| SCR Disease Name: | Thrombophilia, hereditary |
| تواريخ الأحداث: | Date Created: 20230104 Date Completed: 20230228 Latest Revision: 20230302 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1002/jmv.28457 |
| PMID: | 36597901 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.28457 |